Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.53 |
| ▸ | CCND1 | P24385 | 12/20 | 0.50 |
| ▸ | CDK1 | P06493 | 4/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.50 |
| ▸ | FLT3 | P36888 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.48 |
| ▸ | CCND2 | P30279 | 3/20 | 0.48 |
| ▸ | CCND3 | P30281 | 3/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727715 | 1.00 | CDK4 (0.53) | CDK4CDK6CCND1CDK1CCNB1 | |
| SCHEMBL2564026 | 0.90 | CDK4 (0.53) | CDK4CDK6CCND1CDK1CCNB1 | |
| SCHEMBL1115465 | 0.89 | CDK4 (0.51) | CDK4CDK6CCND1CDK1CCNB1 | |
| SCHEMBL2568469 | 0.88 | CCND1 (0.51) | CDK4CDK6CCND1CDK1CCNB1 | |
| SCHEMBL1115336 | 0.88 | CDK4 (0.50) | CDK4CDK6CCND1CDK1CCNB1 | |
| SCHEMBL1115284 | 0.80 | CDK4 (0.49) | CDK4CDK6CCND1FGFR1FGFR2 | |
| SCHEMBL1643147 | 0.80 | CDK4 (0.51) | CDK4CDK6CCND1CDK1CCNB1 | |
| SCHEMBL1115483 | 0.78 | CDK4 (0.52) | CDK4CDK6CCND1CDK1FGFR1 | |
| SCHEMBL1643493 | 0.78 | CDK4 (0.51) | CDK4CDK6CCND1CDK1FGFR1 | |
| SCHEMBL1115188 | 0.77 | CDK6 (0.51) | CDK4CDK6CCND1FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | claimed |
| EP-2278973-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2011-02-02 | — | — | EP | claimed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | claimed |
| US-8389533-B2 | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors | AMGEN INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2278973-B1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | AMGEN INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2278973-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | Amgen Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009126584-A1 | GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097305-A1 | Gem-Disubstituted and Spirocyclic Amino Pyridines/Pyrimidines as Cell Cycle Inhibitors | CDK4, CDK3, CDK6 | CDK4 1/4885CDK6 3/4885CCND1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.